GLP-1 agonists

Background

• Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
• Released by L-cells of the small intestinge in response to the presence of nutrients
• Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas
• Slows gastric emptying times
• Increases satiety, which decreases drive for food intake

Types

Short Acting	Dose
Exenatide(Byetta)	5-10 mcg SC bid
Liraglutide(Victoza)	0.6-1.8 mg SC daily
Long Acting
Exenatide(Bydureon)	2 mg SC qwk
Albiglutide(Tanzeum)	30-50 mg SC qwk
Dulaglutide(Trulicity)	0.75-1.5 mg qwk

Indication

• Diabetes Mellitus, Type 2

Adverse Reactions

• Nausea, vomiting, diarrhea
• Acute pancreatitis
• Exenatide should not be used in patients with creatinine clearance below 30mL/min
• Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B

See Also

Diabetes medications

References

1.Epocrates

2.http://www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus?source=see_link&sectionName=GLUCAGON-LIKE+PEPTIDE-1&anchor=H2#H619400

Authors

Mark Monterroso, Anthony Lucero, Claire, Neil Young